2. Search Result
Search Result
Results for "

BRK

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

3

Recombinant Proteins

1

Isotope-Labeled Compounds

7

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-110244
    Tilfrinib

    		BRK Cancer
    Tilfrinib (compound 4f) is a potent and selective Brk/PTK6 inhibitor with an IC50 value of 3.15 nM for Brk. Tilfrinib shows good anti-proliferative activity and has potential of anti-tumour .
    Tilfrinib
  • HY-171830
    MS105

    YX39-105

    		 PROTACs Tyrosinase Apoptosis Cancer
    MS105 (YX39-105) is an orally active and selective protein tyrosine kinase 6 (PTK6) (BRK) PROTAC degrader. MS105 recruits VHL E3 ligase via a VHL ligand moiety, promotes PTK6 ubiquitination and proteasomal degradation, inhibits the proliferation and migration of breast cancer cells, and induces apoptosis. MS105 shows potential for use in breast cancer research .
    MS105
  • HY-108333
    SB-633825
    4 Publications Verification

    		 Ser/Thr Kinase Cardiovascular Disease Cancer
    SB-633825 is a potent and ATP-competitive inhibitor of TIE2, LOK (STK10) and BRK with IC50s of 3.5 nM, 66 nM, 150 nM, respectively. SB-633825 can inhibit cancer cell growth and angiogenesis .
    SB-633825
  • HY-115514A
    BRK inhibitor P21d hydrochloride

    		BRK Cancer
    BRK inhibitor P21d hydrochloride is a potent breast tumor kinase (BRK/PTK6) inhibitor with an IC50 of 30 nM. BRK inhibitor P21d hydrochloride inhibits p-SAM68 with an IC50 of 52 nM. BRK inhibitor P21d hydrochloride can be used to evaluate the in vivo activity of BRK inhibitors in xenograft breast tumor models .
    BRK inhibitor P21d hydrochloride
  • HY-122664
    XMU-MP-2

    		BRK Apoptosis STAT ERK Akt Cancer
    XMU-MP-2 is a selective BRK/PTK6 inhibitor with an IC50 of 5.4 nM. XMU-MP-2 inhibits the proliferation of BRK-positive breast cancer cells and induces apoptosis. XMU-MP-2 is applicable to breast cancer-related research .
    XMU-MP-2
  • HY-178460
    BRK/PTK6-IN-1

    		BRK Akt MMP Cancer
    BRK/PTK6-IN-1 (Compound 51) is a highly efficient and selective BRK inhibitor (IC50 = 3.37 nM, Kd = 44 nM). BRK/PTK6-IN-1 can reduce MMP-9 protein expression and inhibit IGF-1 induced AKT phosphorylation in MDA-MB-231 cells. BRK/PTK6-IN-1 significantly inhibits migration, invasion, and colony formation but does not affect cell proliferation. BRK/PTK6-IN-1 is often used in the research of breast cancer and other cancers .
    BRK/PTK6-IN-1
  • HY-RS11403
    PTK6 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    PTK6 Human Pre-designed siRNA Set A contains three designed siRNAs for PTK6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PTK6 Human Pre-designed siRNA Set A
    PTK6 Human Pre-designed siRNA Set A
  • HY-RS01625
    BRK1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    BRK1 Human Pre-designed siRNA Set A contains three designed siRNAs for BRK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    BRK1 Human Pre-designed siRNA Set A
    BRK1 Human Pre-designed siRNA Set A
  • HY-E70725
    FRK Recombinant Human Active Protein Kinase

    		Src Cancer
    FRK Recombinant Human Active Protein Kinase, a non-receptor tyrosine kinase Fyn-related kinase, is a member of the BRK family kinases (BFKs). FRK may be involved in tumor progression .
    FRK Recombinant Human Active Protein Kinase
  • HY-155227S
    ALK/EGFR-IN-1-d5

    		Isotope-Labeled Compounds EGFR Anaplastic lymphoma kinase (ALK) BRK Apoptosis Mitochondrial Metabolism Cancer
    ALK/EGFR-IN-1-d5 (Compound (-)-9a) is a deuterated dual-target inhibitor of EGFR and ALK, with an IC50 of 1.08 nM for EGFR and an IC50 of 2.395 nM for ALK. ALK/EGFR-IN-1-d5 inhibits the phosphorylated proteins in the EGFR, ALK, and BRK signaling pathways, blocking the cell cycle, leading to a reduction in mitochondrial membrane potential and cell apoptosis (Apoptosis). ALK/EGFR-IN-1-d5 also significantly inhibits tumor growth in animal models and demonstrates good safety. ALK/EGFR-IN-1-d5 holds promise for research in the field of cancer treatment
    ALK/EGFR-IN-1-d5
  • HY-123597
    NSC 109555

    DDUG; NCI C04808

    		 Autophagy Checkpoint Kinase (Chk) Cancer
    NSC 109555 is an ATP-competitive inhibitor of checkpoint kinase 2 (Chk2; IC50=200 nM in a cell-free kinase assay). It is selective for Chk2 over Chk1 and 16 kinases in a panel but does inhibit Brk, c-Met, IGFR, and LCK with IC50 values of 210, 6,000, 7,400, and 7,100 nM, respectively. NSC 109555 inhibits Chk2 autophosphorylation and phosphorylation of the Chk2 substrate histone H1 in vitro (IC50=240 nM). It inhibits the growth of, and induces autophagy in, L1210 leukemia cells in vitro.2 NSC 109555 (1,250 nM) potentiates gemcitabine-induced cytotoxicity in MIA PaCa-2, CFPAC-1, PANC-1, and BxPC-3 pancreatic cancer cells, as well as reduces gemcitabine-induced increases in Chk2 phosphorylation and enhances gemcitabine-induced production of reactive oxygen species (ROS) in MIA PaCa-2 cells.
    NSC 109555
  • HY-108333R
    SB-633825 (Standard)

    		Ser/Thr Kinase Reference Standards Cardiovascular Disease Cancer
    SB-633825 (Standard) is the analytical standard of SB-633825 (HY-108333). This product is intended for research and analytical applications. SB-633825 is a potent and ATP-competitive inhibitor of TIE2, LOK (STK10) and BRK with IC50s of 3.5 nM, 66 nM, 150 nM, respectively. SB-633825 can inhibit cancer cell growth and angiogenesis .
    SB-633825 (Standard)
  • HY-RS17542
    Ptk6 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Ptk6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ptk6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ptk6 Mouse Pre-designed siRNA Set A
    Ptk6 Mouse Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: